Tech Company Financing Transactions
Ocugen Funding Round
EB5 Life Sciences, Global City Regional Center and private investors participated in a $6 million Series A capital raise for Ocugen. This VC investment round was announced on 12/17/2016.
Transaction Overview
Company Name
Announced On
12/17/2016
Transaction Type
Venture Equity
Amount
$6,000,000
Round
Series A
Investors
Proceeds Purpose
With this funding, we will continue our efforts to aggressively advance the OCU300 program toward an IND submission within a year, bringing this much needed therapy closer to the patients who need it.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5 Great Valley Pkwy. 160
Malvern, PA 19355
USA
Malvern, PA 19355
USA
Phone
Website
Email Address
Not Recorded
Overview
Ocugen is advancing two novel biologicals and a marketed drug product as a re-purposed drug under the U.S. Food and Drug Administration's 505(b)(2) regulatory pathway to treat sight threatening ocular disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Shankar Musunuri
Chief Financial Officer
Sanjay Subramanian
Chief Medical Officer
Mohamed Genead
Chief Scientific Officer
Rasappa Arumugham
Controller
Jessica Crespo
VP - Regulatory Affairs
Vijay Tammara
Browse more venture capital transactions:
Prev: 12/17/2016: Medisas venture capital transaction
Next: 12/17/2016: Nexamp venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs